To address the challenge of target heterogeneity that limits the efficacy of classical antibody-drug conjugates, we deployed this novel platform to harness the radiation deposited in LRRC15+ cells to eliminate adjacent LRRC15-null tumor tissue. Here, LRRC15 is linked to neoplasm.